Otsuka Acquires Rights to Hematological Cancer Treatment Dacogen from Eisai

Otsuka Pharmaceutical Co., Ltd. has announced an agreement with Eisai Inc. , a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment Dacogen and to an enzyme inhibitor, E7727.

http://ift.tt/1fd9alj